WVE News

As we noted in a mid-week blog post, AAAP had the best first-day pop (+53%) for an IPO in three months, and on the same day Voyager had the best pop in almost two months (+27%). While there were no biotech filings this past week, it is a safe...read more

Three biotechs and one regional bank priced and began trading on Wednesday. None broke issue. Only one of the four priced below the range, compared to 85% of IPOs that began trading in October. Advanced Accelerator Applications (AAAP) popped 53%, giving it the best first-day performance for an IPO in the past three months. The diagnostics/therapeutics...read more

WAVE Life Sciences, a preclinical biotech developing optimized RNA therapies for rare diseases, raised $102 million by offering 6.4 million shares at $16, the midpoint of the range of $15 to $17. The company originally planned to offer 5.0 million shares. Existing investors and Teva plan to buy $62 million on the IPO (61% of the deal). WAVE Life Sciences plans to list on the Nasdaq...read more

Silenseed, a biotech developing RNA interference cancer drugs and delivery systems, withdrew its plans for an initial public offering on Tuesday. The company has first targeted pancreatic cancer for its combined RNA interference (RNAi) drug and delivery platform, which enables cancer therapies to be implemented directly into the core of solid tumors. Recent RNA biotechs Mirna...read more